TrialAmerican journal of clinical dermatology2024

Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure.

Eric L Simpson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.